Top

Published in:

01-12-2006 | Review Article

Current Pharmacological Options for the Management of Primary Hyperparathyroidism

Author: Dr Peter Vestergaard

Published in: Drugs | Issue 17/2006

Abstract

Drugs for treating primary hyperparathyroidism can be divided into two main groups: (i) antiresorptive drugs that inhibit the increased bone turnover, which can be divided into estrogen-like compounds (estrogen, oral contraceptives and selective estrogen receptor modulators [SERMs]), bisphosphonates and calcitonin; and (ii) drugs that interfere with parathyroid hormone (PTH) secretion (currently only cinacalcet is available). No drugs that interfere with PTH action are currently available.

Available studies suggest that all classes of drugs are able to lower serum calcium levels. However, calcitonin does so only temporarily. Estrogen-containing compounds (hormone replacement therapy) may be less attractive because of the potential risk of breast cancer, cardiovascular disease and deep vein thromboembolism. Oral contraceptives have not been shown to be able to prevent fractures in the general population, and no data are available on their effect in women with primary hyperparathyroidism. The only SERM marketed for hyperparathyroidism is raloxifene and this has not been associated with an increased risk of breast cancer and cardiovascular diseases, and has been shown to be able to prevent vertebral fractures in postmenopausal women with osteoporosis. Two small trials suggest that raloxifene may increase bone mineral density (BMD) and decrease serum calcium levels in patients with primary hyperparathyroidism. Bisphosphonates have been shown to decrease serum calcium and increase BMD in patients with primary hyperparathyroidism, but PTH levels may increase.

Cinacalcet effectively induces a sustained decrease in serum calcium and PTH for up to 1 year. However, BMD does not seem to increase.

No data on hard endpoints such as fractures, kidney stones, cardiovascular disease etc. are available for any of the drugs available for the treatment of primary hyperparathyroidism.

Jüppner H, Kronenberg HM. Parathyroid hormone. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society for Bone and Mineral Research, 2003: 117–25

Joy MS, Kshirsagar AV, Franceschini N. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother 2004; 38: 1871–80PubMedCrossRef

Eriksen EF, Mosekilde L, Meisen F. Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone 1986; 7: 213–21PubMedCrossRef

Charles P, Mosekilde L, Jensen FT. Primary hyperparathyroidism: evaluated by 47calcium kinetics, calcium balance and serum bone-Gla-protein. Eur J Clin Invest 1986; 16: 277–83PubMedCrossRef

Rao DS, Wilson RJ, Kleerekoper M, et al. Lack of biomechanical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988; 67: 1294–8PubMedCrossRef

Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 1995; 80: 729–34PubMedCrossRef

Wilson RJ, Rao S, Ellis B, et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988; 109: 959–62PubMed

Moosgaard B, Vestergaard P, Heickendorff L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005; 63: 506–13CrossRef

Mundy GR, Cove DH, Fisken R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1980; I: 1317-20CrossRef

10.

Bilezikian JP, Potts JT Jr, Fuleihan G, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87: 5353–61PubMedCrossRef

11.

Mollerup CL, Vestergaard P, Frøkjær VG, et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 2002; 325: 807–12PubMedCrossRef

12.

Smith JC, Page MD, John R, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 3515–9PubMedCrossRef

13.

Sancho JJ, Roucho J, Riera-Vidal R, et al. Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg 1992; 16: 732–6PubMedCrossRef

14.

Paloyan D, Simonowitz D, Paloyan E, et al. Pancreatitis associated with primary hyperparathyroidism. Am Surg 1982; 48: 366–8PubMed

15.

Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002; 19: 958–61PubMedCrossRef

16.

Vestergaard P, Mollerup CL, Frøkjær VG, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000; 321: 598–602PubMedCrossRef

17.

Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism: an update. Eur J Clin Invest 1998; 28: 271–6PubMedCrossRef

18.

Hedbäck G, Oden A, Tisell LE. The influence of surgery on the risk of death in patients with primary hyperparathyroidism. World J Surg 1991; 15: 399–405PubMedCrossRef

19.

Vestergaard P, Mosekilde L. Cohort study on the effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003; 327: 530–5PubMedCrossRef

20.

Eigelberger MS, Cheah WK, Ituarte PH, et al. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg 2004; 239: 528–35PubMedCrossRef

21.

Vestergaard P. Anti-resorptive therapy for the prevention of postmenopausal osteoporosis: when should treatment begin? Treat Endocrinol 2005; 4: 263–77PubMedCrossRef

22.

Gallagher JC, Nordin BEC. Effects of oestrogen and progestogen therapy on calcium metabolism in post-menopausal women. Front Horm Res 1975; 3: 150–76PubMed

23.

Gallagher JC, Nordin BEC. Treatment with oestrogens of primary hyperparathyroidism in post-menopausal women. Lancet 1972; I: 503–7CrossRef

24.

Gallagher JC, Wilkinson R. The effect of ethinyloestradiol on calcium and phosphorus metabolism of postmenopausal women with primary hyperparathyroidism. Clin Sci Mol Med 1973; 45: 785–802PubMed

25.

Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986; 314: 1481–5PubMedCrossRef

26.

Marcus R, Madvig P, Crim M, et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984; 100: 633–40PubMed

27.

Haldimann B, Trechsel U, Dambacher MA, et al. Hyperparathy-roidie primaire de la femme agee: effect des oestrogenes sur le metabolism calcique [summary in English]. Schweiz Med Wochenschrift 1982; 112: 1242–5

28.

Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomised controlled trial. Ann Intern Med 1996; 125: 360–8PubMed

29.

Diamond T, Ng AT, Levy S, et al. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Oste-oporos Int 1996; 6: 329–33CrossRef

30.

Herbai G, Ljunghall S. Treatment of primary hyperparathyroidism with cyclofenil: a synthetic stilbestrol derivative with minimal feminizing effects. Horm Metab Res 1984; 16: 374–6PubMedCrossRef

31.

Herbai G, Ljunghall S. Normalization of hypercalcaemia in primary hyperparathyroidism by treatment with methallenes-tril, a synthetic oestrogen with low oestrogeneicity. Urol Int 1983; 38: 371–3PubMedCrossRef

32.

Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000; 61: 77–82PubMedCrossRef

33.

Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fractures. Contraception 2006; 73: 571–6PubMedCrossRef

34.

Cooper C, Hannaford P, Croft P, et al. Oral contraceptive pill use and fractures in women: a prospective study. Bone 1993; 14: 41–5PubMedCrossRef

35.

Michaelsson K, Baron JA, Farahmand BY, et al. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 1999; 353: 1481–4PubMedCrossRef

36.

Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture: findings in a large cohort study. Contraception 1998; 57: 231–5PubMedCrossRef

37.

Goldfien A. The gonadal hormones & inhibitors. In: Katzung BG, editor. Basic and clinical pharmacology. East Norwalk (CT): Appleton & Lange, 1987: 461–83

38.

McDermott MT, Perloff JJ, Kidd GS. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Mineral Res 1994; 9: 509–14CrossRef

39.

Risks and benefits of estrogen plus progestin in healthy postme-nopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33

40.

Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1729–38PubMedCrossRef

41.

The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12CrossRef

42.

Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891–7PubMedCrossRef

43.

Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001; 2: 7–10PubMedCrossRef

44.

Vestergaard P, Rejnmark L, Mosekilde L. Fracture reducing potential of hormone replacement therapy on a population level. Maturitas 2006; 54: 285–93PubMedCrossRef

45.

Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942–4PubMedCrossRef

46.

Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37PubMed

47.

Horowitz M, Wishart J, Need AG, et al. Treatment of postmenopausal hyperparathyroidism with norethindrone. Arch Intern Med 1987; 147: 681–5PubMedCrossRef

48.

Zanchetta JR, Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 2001; 16: 189–90PubMedCrossRef

49.

Rubin MR, Lee KH, McMahon DJ, et al. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 1174–8PubMedCrossRef

50.

Stone MD, Marshall DH, Hosking DJ, et al. Comparison of low-dose intramuscular and intravenous salcatonin in the treatment of primary hyperparathyroidism. Bone 1992; 13: 265–71PubMedCrossRef

51.

Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609–17PubMedCrossRef

52.

Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637–45PubMedCrossRef

53.

Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751–61PubMedCrossRef

54.

Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847–57PubMedCrossRef

55.

Torring O, Bucht E, Sjostedt U, et al. Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism. Bone 1991; 12: 311–6PubMedCrossRef

56.

Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 540–51PubMedCrossRef

57.

Chesnut CH III, Silverman S, Andriano KA, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109: 267–76

58.

Rossini M, Gatti D, Isaia G, et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Mineral Res 2001; 16: 113–9CrossRef

59.

Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 3319–25PubMedCrossRef

60.

Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 581–7PubMedCrossRef

61.

Parker CR, Blackwell PJ, Fairbairn KJ, et al. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 2002; 87: 4482–9PubMedCrossRef

62.

LoCascio V, Braga V, Bertoldo F, et al. Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994; 41: 47–51CrossRef

63.

Adami S, Zamberlan N, Mian M, et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget’s disease of bone. Bone Miner 1994; 25: 75–82PubMedCrossRef

64.

Horiuchi T, Onouchi T, Inoue J, et al. A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathy-roidectomy. Gerontology 2002; 48: 103–8PubMedCrossRef

65.

Hamdy NA, Gray RE, McCloskey E, et al. Clodronate in the medical management of hyperparathyroidism. Bone 1987; 8: S69–77PubMed

66.

Shane E, Baquiran DC, Bilezikian JP. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 1981; 95: 23–7PubMed

67.

Douglas DL, Kanis JA, Paterson AD, et al. Drug treatment of primary hyperparathyroidism: use of clodronate disodium. BMJ (Clin Res Ed) 1983; 286: 587–90CrossRef

68.

Ammann P, Herter-Clavel C, Lubrano A, et al. A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism. Aging Clin Exp Res 2003; 15: 500–4PubMed

69.

Reasner CA, Stone MD, Hosking DJ, et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993; 77: 1067–71PubMedCrossRef

70.

Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508–16PubMedCrossRef

71.

Black DM, Cummings SR, Kerpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41PubMedCrossRef

72.

Douglas DL, Duckworth T, Russell RG, et al. Effect of dichloromethylene diphosphonate in Paget’s disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1980; 1: 1043–7PubMedCrossRef

73.

Hoffmeyer P, Groebli Y, Spiliopoulos A, et al. Clodronate therapy of hypercalcemia caused by hyperparathyroidism [in German]. Schweiz Med Wochenschr 1982; 112: 118–20PubMed

74.

McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004; 19: 728–36PubMedCrossRef

75.

Licata AA, O’Hanlon E. Treatment of hyperparathyroidism with etidronate sodium. JAMA 1983; 249: 2063–4PubMedCrossRef

76.

Kaplan RA, Geho WB, Poindexter C, et al. Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol 1977; 37: 410–9

77.

Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Int 2001; 12: 140–51CrossRef

78.

Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517–23PubMedCrossRef

79.

Häuselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis Int 2003; 14: 2–12CrossRef

80.

Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057–64PubMedCrossRef

81.

Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 1595–9PubMedCrossRef

82.

de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016–21PubMedCrossRef

83.

Quarles LD. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens 2003; 12: 349–55PubMedCrossRef

84.

Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 135–41PubMedCrossRef

85.

Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 5644–9PubMedCrossRef

86.

Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodi-alysis. N Engl J Med 2004; 350: 1516–25PubMedCrossRef

87.

Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248–54PubMedCrossRef

88.

Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575–83PubMedCrossRef

89.

Rubin M, Sliney J, McCary LC, et al. Effective management of severe hypercalcemia with the calcimimetic cinacalcet HCI in patients with parathyroid carcinoma. J Bone Miner Res 2003; 18 Suppl. 2: S392

90.

Rubin MR, Sliney J, Silverberg SJ, et al. Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCl. J Bone Miner Res 2004; 19 Suppl. 1: S103

91.

Silverberg SJ, Faiman C, Bilezikian JP, et al. Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma. J Bone Miner Res 2004; 19 Suppl. 1: S103

92.

Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017–24PubMed

93.

Hasling C, Charles P, Mosekilde L. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study. Euro J Clin Invest 1986; 16: 433–7CrossRef

94.

Pecherstorfer M, Brenner K, Zojer N. Current management strategies for hypercalcemia. Treat Endocrinol 2003; 2: 273–92PubMedCrossRef

95.

Wisneski LA, Croom WP, Silva OL, et al. Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 1978; 24: 219–22PubMed

96.

Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; 2: 1180–2PubMedCrossRef

97.

Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996; 14: 158–70PubMedCrossRef

98.

Kantorovich V, Gacad MA, Seeger LL, et al. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathy-roidism. J Clin Endocrinol Metab 2000; 85: 3541–3PubMedCrossRef

99.

Lind L, Wengle B, Sorensen OH, et al. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism. Acta Endocrinol (Copenh) 1989; 120: 250–6

100.

Broadus AE, Magee JS, Mallette LE, et al. A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism. J Clin Endocrinol Metab 1983; 56: 953–61PubMedCrossRef

101.

Ljunghall S, Rudberg C, Åkerström G, et al. Effects of beta-adrenergic blockade on serum parathyroid hormone in normal subjects and patients with primary hyperparathyroidism. Acta Med Scand 1982; 211: 27–30PubMedCrossRef

102.

Fisken RA, Wilkinson R, Heath DA. The effects of cimetidine on serum calcium and parathyroid hormone levels in primary hyperparathyroidism. Br J Clin Pharmacol 1982; 14: 701–5PubMedCrossRef

103.

Wiske PS, Epstein S, Norton JA Jr, et al. The effects of intravenous and oral cimetidine in primary hyperparathyroidism. Horm Metab Res 1983; 15: 245–8PubMedCrossRef

Title: Current Pharmacological Options for the Management of Primary Hyperparathyroidism
Author: Dr Peter Vestergaard
Publication date: 01-12-2006
Publisher: Springer International Publishing
Published in: Drugs / Issue 17/2006
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666170-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current Pharmacological Options for the Management of Primary Hyperparathyroidism

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 17/2006

Blood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease

Efficacy and Safety of Budesonide and Formoterol in One Pressurised Metered-Dose Inhaler in Adults and Adolescents with Moderate to Severe Asthma

Tacrolimus: In Heart Transplant Recipients

Sunitinib

Tacrolimus: In Heart Transplant Recipients

Tacrolimus: In Heart Transplant Recipients